PHILADELPHIA, Jan. 30, 2026 (GLOBE NEWSWIRE) -- WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) as a securities fraud class action has now reached a settlement. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. Current Lifecore Biomedical, Inc. (NASDAQ: LFCR) who have held shares since before October 7, 2020, can seek corporate reforms, the return of fund ...

对长三角万亿GDP城市而言，产业质量正成为更长周期的竞争变量。 | | 长三角万亿之城2025年经济数据 | | | --- | --- | --- | | 城市 | 2025年GDP总量(万亿元) | 2025年GDP増速 | | 上海 | 5.67 | 5.4% | | 苏州 | 预计2.77 | 预计5.4%左右 | | 杭州 | 2.3 | 5.2% | | 南京 | | 预计5.2%左右 | | 宁波 | 1.87 | 4.9% | | 无锡 | 预计1.68左右 | 预计5.1%左右 | | 合肥 | | 预计6%左右 | | 南道 | 预计1.3 | 预计5.3% | | 常州 | | 预计5.2%左右 | | 温州 | 1.02 | 6.1% | | | 数据来源:各城市统计局、各城市2026年政府工作报告 | | | 敕阳· 加宁超 | | | 对于长三角万亿之城而言，GDP规模仍然重要，但已不再是唯一指标。产业结构是否合理、新旧动能能否接续，正在成为衡量 一座城市发展质量的重要维度。 2025年，上海经济在稳增长与结构升级中继续向前，全年地区生产总值达56708.71亿元，同比增长5.4% ...

Core Insights - Curative Biotechnology, Inc. has received a Notice of Allowance for a Canadian patent related to a novel pharmacological target for treating retinal degeneration, which is a significant advancement for the company [1][3] - The company holds an exclusive worldwide license for this technology from the National Eye Institute, indicating a strong partnership with a reputable institution [1][6] - Curative plans to expand its metformin-based eye drop program into veterinary applications, specifically targeting canine retinal degenerative diseases, which may enhance the overall value of its platform [4][5] Intellectual Property - The Canadian patent includes 22 allowed claims focused on topical ocular delivery methods relevant to metformin-based formulations, aligning with the company's intended administration route [3] - The patent is expected to be formally issued in the coming months, further solidifying the company's intellectual property portfolio [3] Development Plans - Curative's primary focus is on developing a metformin-based reformulation for treating intermediate and late-stage Age-Related Macular Degeneration (AMD), with a first-in-human clinical trial planned for 2026 [6] - The company is also exploring parallel development pathways in veterinary ophthalmology, addressing unmet needs in canine retinal diseases [4][5]

Core Insights - Quanterix Corporation announced the publication of a significant study in JAMA Network Open, highlighting its role in advancing healthcare through biomarker research [1] Company Overview - Quanterix Corporation is focused on transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics [1] Study Details - The study was conducted by researchers at Amsterdam UMC and followed nearly 300 individuals for up to 15 years [1] - The findings of the study are expected to have a substantial impact on the understanding of biomarkers in healthcare [1]

Core Insights - GelrinC-treated patients showed layered cartilage architecture similar to native hyaline cartilage, indicating true biological cartilage regeneration rather than just defect filling [1] - GelrinC limits fibrotic tissue overgrowth, which supports smoother joint motion and preserves natural biomechanics [1] Company Overview - Regentis Biomaterials Ltd. is a regenerative medicine company focused on innovative tissue repair solutions [1] - The company announced new long-term imaging data from a completed European clinical trial of GelrinC® [1] Clinical Trial Results - The clinical trial demonstrated that regenerated cartilage exhibits internal structural organization closely resembling healthy, native hyaline cartilage [1]

Core Viewpoint - Disc Medicine, Inc. (NASDAQ:IRON) is positioned positively in the healthcare sector, with an "Outperform" rating from Wedbush, indicating confidence in its potential to outperform market averages [1][6]. Group 1: Company Performance - The current stock price of IRON is approximately $72.46, reflecting a decrease of about 6% or $4.62 from previous levels [3][6]. - The stock has shown volatility, with a daily trading range between $71 and $77.07, and over the past year, it has fluctuated significantly, reaching a high of $99.50 and a low of $30.82 [3][6]. - Disc Medicine's market capitalization is around $2.74 billion, indicating its size and market value within the healthcare sector [4]. Group 2: Investor Engagement - The company recently presented at the 44th Annual J.P. Morgan Healthcare Conference, a significant event for healthcare firms to showcase their advancements and engage with investors [2][5]. - The trading volume of 679,355 shares on the NASDAQ suggests active investor interest, reflecting the market's response to recent developments [4][5].

时光悠然,芬芳满径。乙巳蛇年的华章渐近尾声,丙午马年的序曲即将奏 响。 "浦江同舟"连续第三年推出《"图"结向未来》专栏,通过一张张图片、一 个个身影、一项项实事、一场场活动,回顾上海统一战线贴近大局、融入 大局、服务大局,推动高质量发展的这一年。 一起来看市欧美同学会的2025年→ 、成功审建海归小镇,打造归国人才创新高地 海归小镇(奉贤·生物科技)申建成功,全国人大常委会副委员长、欧美 同学会会长丁仲礼出席揭牌仪式。与奉贤区、临港集团构建三方协同工 作机制,共同主办上海首届海归小镇留学生嘉年华,打造"校长来了""海 归职通车""海创路演""海归市集"四大板块,吸引7所中外高校校长、56 家头部企业900余岗位及1800余留学人员参与。 、联学联建聚合力,理论武装筑信仰 深入贯彻落实中央八项规定精神学习教育,开展全国两会、党的二十届 四中全会精神、《习近平谈治国理政》第五卷学习活动。举办"丰子恺民 族精神艺术展""纪念抗战胜利80周年观影"等活动,打造"留学档案见证 百年复兴路"精品党课并入选市委组织部党课矩阵,引导留学人员凝聚思 想共识,筑牢理想信念根基。 五、发挥青委会组织优势,服务青年会员成长发展 三 ...

Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. regarding a securities fraud class action settlement, focusing on potential breaches of fiduciary duties by certain officers and directors [1][3]. Group 1: Settlement and Investigation - A federal securities class action against Lifecore Biomedical has reached a settlement, alleging that the company made materially false and misleading statements about its business and financial operations [3]. - The investigation is centered on whether Lifecore maintained adequate internal controls over financial reporting, which led to inaccurate financial statements that required restatement [3]. - The settlement allows shareholders who held shares before October 7, 2020, to seek corporate reforms and the return of funds to the company at no cost [2][4]. Group 2: Allegations and Implications - The class action complaint claims that Lifecore's remediation efforts regarding financial reporting deficiencies were ineffective, impairing its ability to file timely reports with the SEC [3]. - The allegations suggest that Lifecore's financial position and prospects were materially overstated, leading to misleading public statements throughout the relevant period [3].

Group 1 - The core event is the signing of 29 investment projects in Banan District, Chongqing, with a total investment of approximately 22 billion yuan [1] - The signed projects cover key industrial sectors including biomedicine, electronic information, intelligent connected new energy vehicles, technology services, financial services, and modern logistics [1]

Group 1 - Advanced Biomed Inc. has entered into an agreement to sell 100% of its Hong Kong subsidiary for a total purchase price of US$23,000 based on a valuation report [1] - The transaction includes the transfer of all intellectual property owned by the Hong Kong subsidiary, including that of its wholly owned subsidiary, Shanghai Sglcell Biotech Co., Ltd. [2] - The CEO of Advanced Biomed stated that the divestment is part of a strategic realignment to centralize clinical trials in Taiwan due to evolving regulatory requirements in China [3] Group 2 - The company operates through its Taiwan subsidiary, which has developed a proprietary microfluidic platform for advanced circulating tumor cell detection and analysis [4] - The product portfolio includes devices and biochips designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for global expansion [4]